DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling

Experimental Cell Research

Volumn 299, Issue 1, 2004, Pages 91-100

  Mamoune, Asmaa ^a,b   Kassis, Jareer ^a,b   Kharait, Sourabh ^a,b   Kloeker, Susanne ^c   Manos, Elisabeth ^c   Jones, David A ^c   Wells, Alan ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

EGF receptor; Migration; Motility; Phospholipase C ; Tumor progression

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AMILORIDE; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIGEL; PHOSPHOLIPASE C INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RECEPTOR ANTIBODY; UROKINASE RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME SYNTHESIS; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN CONTENT; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

MUS MUSCULUS;

EID: 4043107045     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.05.008     Document Type: Article

References (54)

1. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res. 78:2000;31-101
2. Aaronson S.A. Growth factors and cancer. Science. 254:1991;1146-1153
3. Kim H., Turner T., Kassis J., Souto J., Wells A. EGF receptor signaling in prostate development. Histol. Histopathol. 14:1999;1175-1182
4. Glading A., Lauffenburger D.A., Wells A. Cutting to the chase: calpain proteases in cell migration. Trends Cell Biol. 12:2002;46-54
5. Malliri A., Symons M., Hennigan R.F., Hurlstone A.F.L., Lamb R.F., Wheeler T., Ozanne B.W. The transcriptional factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J. Cell Biol. 143:1998;1087-1099
6. Manos E.J., Kim M., Kassis J., Chang B., Wells A., Jones D.A. Prostin-1, a novel phospholipase C-γ regulated gene negatively associated with prostate tumor invasion. Oncogene. 20:2001;2781-2790
7. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57:2000;25-40
8. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev., Mol. Cell Biol. 3:2002;932-943
9. Liu D.F., Rabbani S.A. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate. 27:1995;269-276
10. Miyake H., Hara I., Yamanaka K., Arakawa S., Kamidono S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int. J. Oncol. 14:1999;535-541
11. Rabbani S.A., Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 62:2002;2390-2397
12. Sidenius N., Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implications for prognosis and therapy. Cancer Metastasis Rev. 22:2003;205-222
13. Liu D., Aguirre-Ghiso J.A., Estrada Y., Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 1:2002;445-457
14. MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell. 12:2001;863-879
15. Jo M., Thomas K.S., O'Donnell D.M., Gonias S.L. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J. Biol. Chem. 278:2003;1642-1646
16. Unlu A., Leake R.E. The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines. Int. J. Biol. Markers. 18:2003;139-146
17. Shiratsuchi T., Ishibashi H., Shirasuna K. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. J. Cell. Physiol. 193:2002;340-348
18. Jensen P.J., Rodeck U. Autocrine/paracrine regulation of keratinocyte urokinase plasminogen activator through the TGF-alpha/EGF receptor. J. Cell. Physiol. 155:1993;333-339
19. Jarrard D.F., Blitz B.F., Smith R.C., Patai B.L., Rukstalis D.B. Effects of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate. 24:1994;46-53
20. Li Y., Sarkar F. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 186:2002;157-164
21. Turner T., Chen P., Goodly L.J., Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin. Exp. Metastasis. 14:1996;409-418
22. Stone K., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU145). Int. J. Cancer. 21:1978;274-281
23. Xie H., Turner T., Wang M.-H., Singh R.K., Siegal G.P., Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin. Exp. Metastasis. 13:1995;407-419
24. Chen P., Gupta K., Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J. Cell Biol. 124:1994;547-555
25. Turner T., VanEpps-Fung M., Kassis J., Wells A. Molecular inhibition of PLCγ signaling abrogates DU-145 prostate tumor cell invasion. Clin. Cancer Res. 3:1997;2275-2282
26. Hoyer-Hansen G., Ronne E., Solberg H., Behrendt N., Ploug M., Lund L.R., Ellis V., Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267:1992;18224-18229
27. Nguyen D.H., Hussaini I.M., Gonias S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273:1998;18268-18272
28. Busso N., Masur S.K., Lazega D., Waxman S., Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanisms for signal transduction in human epithelial cells. J. Cell Biol. 126:1994;259-270
29. Liu J., Chakraborty C., Graham C.H., Barbin Y.P., Dixon S.J., Lala P.K. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Exp. Cell Res. 286:2003;138-151
30. Jankun J., Skrzypczak-Jankun E. Binding sites of amiloride to urokinase plasminogen activator depends on species. Int. J. Mol. Med. 8:2001;365-371
31. Oka N., Okumura Y., Kanayama H.O., Izaki H., Okamoto M., Kido H., Kagawa S. Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. Eur. Urol. 44:2003;737-741
32. Jankun J., Keck R.W., Skrzypczak-Jankun E., Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 57:1997;559-563
33. Kassis J., Lauffenburger D.A., Turner T., Wells A. Tumor invasion as dysregulated cell motility. Semin. Cancer Biol. 11:2001;105-118
34. Bornfeldt K.E., Raines E.W., Nakano T., Graves L.M., Krebs E.G., Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J. Clin. Invest. 93:1994;1266-1274
35. Kundra V., Escobedo J.A., Kazlauskas A., Kim H.K., Rhee S.G., Williams L.T., Zetter B.R. Regulation of chemotaxis by the platelet-derived growth factor receptor-β Nature. 367:1994;474-476
36. Chen P., Xie H., Sekar M.C., Gupta K.B., Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but MAP kinase activity is not sufficient for induced cell movement. J. Cell Biol. 127:1994;847-857
37. Chen P., Murphy-Ullrich J., Wells A. A role for gelsolin in actuating EGF receptor-mediated cell motility. J. Cell Biol. 134:1996;689-698
38. Chou J., Beer-Stolz D., Burke N., Watkins S.C., Wells A. Distribution of gelsolin and phosphoinositol 4,5-bisphosphate in lamellipodia during EGF-induced motility. Int. J. Biochem. Cell Biol. 34:2002;776-790
39. Kassis J., Moellinger J., Lo H., Greenberg N., Kim H.-G., Wells A. A role for phospholipase C-γ-mediated signaling in tumor cell invasion. Clin. Cancer Res. 5:1999;2251-2260
40. Gong S.J., Rha S.Y., Chung H.C., Yoo N.C., Roh J.K., Yang W.I., Lee K.S., Min J.S., Kim B.S., Chung H.C. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Int. J. Mol. Med. 6:2000;301-305
41. Hudson M., McReynolds M. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J. Natl. Cancer Inst. 89:1997;709-717
42. MacDonald T.J., DeClerk Y.A., Laug W.E. Urokinase induces receptor mediated brain tumor cell migration and invasion. J. Neurooncol. 40:1998;215-226
43. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J.S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53:1993;4143-4147
44. Quattrone A., Fibbi G., Anichini E., Pucci M., Zamperini A., Capaccioli S., Rosso M.D. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger ODNs inhibition of urokinase receptor gene expression. Cancer Res. 55:1995;90-95
45. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 313:1985;144-147
46. Neal D.E., Marsh C., Bennett M.K., Abel P.D., Hall R.R., Sainsbury J.R.C., Harris A.L. Epidermal-growth-factor receptors in human blood cancer: comparison of invasive and superficial tumours. Lancet. i:1985;366-368
47. Sainsbury J.R.C., Farndon J.R., Needham G.K., Malcolm A.J., Harris A.L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. i:1987;1398-1402
48. Estreicher A., Muhlhauser J., Carpentier J., Orci L., Vassalli J. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating edge of monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111:1990;783-792
49. Tang H., Kerins D.M., Hao Q., Inagami T., Vaughan D.E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273:1998;18268-18272
50. Jo M., Thomas K.S., Wu L., Gonias S.L. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J. Biol. Chem. 278:2003;46692-46698
51. Wells A. Molecule in focus: EGF receptor. Int. J. Biochem. Cell Biol. 31:1999;637-643
52. Okusa Y., Ichikura T., Mochizuki H., Shinomiya N. Urokinase type plasminogen activator and its receptor regulates the invasive potential of gastric cancer cell lines. Int. J. Oncol. 17:2000;1001-1005
53. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., Chapman H.A. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol. Biol. Cell. 12:2001;2975-2986
54. Moriyama T., Kataoka H., Hamasuna P., Yoshida E., Sameshima T., Iseda T., Yokogami K., Nakano S., Koono M., Wakisaka S. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin. Exp. Metastasis. 17:1999;873-879